Telix Pharmaceuticals has completed a significant transaction to enhance its theranostic pipeline by acquiring new candidates that target Fibroblast Activation Protein (FAP), a key marker in nuclear medicine for various cancers. In November 2024, the company announced asset purchase and licensing agreements for FAP-targeting radiopharmaceutical candidates developed by Professor Frank Rösch and team at Johannes Gutenberg-Universität Mainz. The lead compound, named TLX400, will be integrated into Telix's development program for bladder cancer and explored for broader applications in solid tumors. The acquired assets are designed to improve tumor retention while reducing off-target effects, addressing challenges of earlier compounds. Telix's CEO of Therapeutics highlighted the potential of this technology for imaging and treating tumors, emphasizing the company's commitment to developing new solutions for urology and pan-cancer treatments.
Thu, 13 Mar 2025 02:18:07 GMT | Biotech Dispatch